PLYMOUTH MEETING, Pa., June 9 GenaeraCorporation (Nasdaq: GENR) announced today a presentation by Genaerascientists of preclinical data on trodusquemine (MSI-1436), Genaera's leaddrug candidate for the treatment of type 2 diabetes and obesity, during the68th Scientific Sessions of the American Diabetes Association in SanFrancisco, California.
The poster presentation, entitled "Trodusquemine (MSI-1436) ImprovesGlucose Tolerance and HbA1C Levels in Murine Models of Insulin Resistance"concluded that treatment with MSI-1436 leads to significant improvements ininsulin sensitivity as well as lower HbA1C levels and weight loss in animalmodels of diabetes. In one study, it was reported that four weekly treatmentsof MSI-1436 administered to ob/ob mice induced significant and dose-dependentreductions in HbA1C levels and body weight. In a separate study, treatment ofdb/db mice with a single dose of MSI-1436 demonstrated a significantimprovement in oral glucose tolerance (OGTT) within 24 hours of dosing, andprior to any significant change in body weight. The scientists concluded thatMSI-1436 may be useful for the treatment of type 2 diabetes and obesity inhumans based on the marked improvements in insulin sensitivity, HbA1C, fastingblood glucose and body weight seen in these studies.
"All of our preclinical work continues to provide very encouraging supportfor our efforts to evaluate MSI-1436 as a therapy for both type 2 diabetes andobesity," stated Jack Armstrong, President and Chief Executive Officer ofGenaera. "We have recently completed dosing in our second Phase 1a study ofMSI-1436 in patients with type 2 diabetes and expect to initiate a plannedPhase 1b (ascending multiple dose) study later this year."
About Trodusquemine (MSI-1436)
Trodusquemine is a centrally and peripherally-acting appetite suppressantand the first highly selective inhibitor of protein tyrosine phosphatase 1B(PTP-1B). PTP-1B is central to controlling the function of both the leptin andinsulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decreaseappetite and normalize blood sugar. Trodusquemine has produced consistent,sustainable weight loss in a variety of animal models and appears to overcomemetabolic readjustment, which often limits sustained weight loss duringcaloric restriction. In addition, trodusquemine has shown the ability toreverse co-morbidities associated with obesity such as abnormal glucosemetabolism and cholesterol elevation.
Genaera Corporation is focused on advancing the science and treatment ofmetabolic diseases. The Company has significant market opportunities with afirst-in-class molecule, trodusquemine (MSI-1436), that has the potential toredefine the treatment paradigm for obesity and type 2 diabetes and ispresently in a phase 1 trial in obesity. In addition, Genaera has avalue-driven, fully out-licensed partnership with MedImmune, Inc. for a secondcore program that is presently undergoing phase 2 clinical testing in asthma.Genaera is committed to directing resources to its core program and theaggressive clinical development of its key assets to build stockholder value.For further information, please see our website at http://www.genaera.com.
This announcement contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 that are subject torisks and uncertainties, known and unknown. Forward-looking statements reflectmanagement's current views and are based on certain expectations andassumptions. Such statements include, among others, statements regarding thepreliminary results, clinical development plans and prospects for Genaera'sprograms including trodusquemine (MSI-1436) and the IL-9 antibody program. Youmay identify some of these forward-looking statements by the use of words inthe statements such as "anticipate," "believe," "continue," "develop,""